Plasma screen

28 May 2009 By Robert Cyran Follow @rob_cyran

The administration made clear its more vigorous approach to competition law. It even laid out targeted areas: health, tech, energy, and agriculture. The FTC s move to block the merger of two drug companies is the first taste of what s in store.

This content is for Subscribers only

Context News

The US Federal Trade Commission stated it will move to block the $3.1bn acquisition of Talecris Biotherapeutics by bloodbased medicine and vaccine producer CSL.

Australia's CSL is the second largest producer of medicines made from plasma, while CSL is the third largest. The FTC says the combination would substantially reduce competition for these drugs in the US market.

Talecris is owned by private equity groups Cerberus and Tribeca Investment Partners.

Email a friend

Please complete the form below.

Required fields *